Rapamycin for cardiac transplant rejection and vasculopathy: One stone, two birds?

Circulation

Volumn 108, Issue 1, 2003, Pages 6-8

  Edelman, Elazer R ^a,b,d   Danenberg, Haim D ^a,c  

^a HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^d MIT Bldg 16 343 ^*  (United States)

Author keywords

Editorials; Rejection; Transplantation; Vasculature

Indexed keywords

ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTIMETABOLITE; ANTITHROMBOCYTIC AGENT; AZATHIOPRINE; CYCLOSPORIN; CYCLOSPORIN A; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; LIPOPROTEIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; SIMVASTATIN; TACROLIMUS;

ANGIOGRAPHY; ANGIOPLASTY; ATHEROSCLEROSIS; CELL INFILTRATION; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DRUG MECHANISM; EDITORIAL; FOLLOW UP; GRAFT REJECTION; GRAFT SURVIVAL; HEART GRAFT; HISTOCOMPATIBILITY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERPLASIA; HYPERTENSION; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; INTIMAL HYPERPLASIA; LIPID STORAGE; MACROPHAGE; PRIORITY JOURNAL; RESTENOSIS; RISK FACTOR; SMOOTH MUSCLE FIBER; SUDDEN DEATH; T LYMPHOCYTE; THROMBOSIS; VASCULAR DISEASE;

ARTERIAL OCCLUSIVE DISEASES; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOSUPPRESSIVE AGENTS; MYCOPHENOLIC ACID; SIROLIMUS;

EID: 0037489296     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000080228.97133.4D     Document Type: Editorial

References (26)

1. De Montaigne ME. De l'institution des enfans. In: Essais. Vol 1, Chapter XXV; 1595.
2. Mancini D, Pinney S, Burkhof D, et al. Use of rapamycin slows progression of cardiac transplant vasculopathy. Circulation. 2003;108:48-53.
3. Costanzo MR, Naftel DC, Pritzker MR, et al. Heart transplant coronary artery disease detected by coronary angiography: a multiinstitutional study of preoperative donor and recipient risk factors. Cardiac Transplant Research Database. J Heart Lung Transplant. 1998;17:744-753.
4. Wenke K, Meiser B, Thiery J, et al. Simvastatin initiated early after heart transplantation: 8-year prospective experience. Circulation. 2003;107:93-97.
5. Carrier M, Pelletier GB, Genest J Jr, et al. Cholesterol-lowering intervention and coronary artery disease after cardiac transplantation. Ann Thorac Surg. 1994;57:353-356.
6. Kobashigawa J, Miller L, Renlund D, et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. Transplantation. 1998;66:507-515.
7. Aranda JM, Pauly DF, Kerensky RA, et al. Percutaneous coronary intervention versus medical therapy for coronary allograft vasculopathy: one center's experience. J Heart Lung Transplant. 2002;21:860-866.
8. Topaz O, Cowley MJ, Mohanty PK, et al. Percutaneous revascularization modalities in heart transplant recipients. Catheter Cardiovasc Interv. 1999;46:227-237.
9. Halle AA 3rd, DiSciascio G, Massin EK, et al. Coronary angioplasty, atherectomy and bypass surgery in cardiac transplant recipients. J Am Coll Cardiol. 1995;26:120-128.
10. Meiser BM, Billingham ME, Morris RE. Effects of cyclosporin, FK506, and rapamycin on graft-vessel disease. Lancet. 1991;338:1297-1298.
11. Morris RE, Cao W, Huang X, et al. Rapamycin (sirolimus) inhibits vascular smooth muscle DNA synthesis in vitro and suppresses narrowing in arterial allografts and in balloon-injured carotid arteries: evidence that rapamycin antagonizes growth factor action on immune and nonimmune cells. Transplant Proc. 1995;27:430-431.
12. Poston RS, Billingham M, Hoyt EG, et al. Rapamycin reverses chronic graft vascular disease in a novel cardiac allograft model. Circulation. 1999;100:67-74.
13. Poon M, Marx SO, Gallo R, et al. Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest. 1996;98:2277-2283.
14. Marx SO, Jayaraman T, Go LO, et al. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res. 1995;76:412-417.
15. Marx SO, Marks AR. Bench to bedside: the development of rapamycin and its application to stent restenosis. Circulation. 2001;104:852-855.
16. Degertekin M, Serruys PW, Foley DP, et al. Persistent inhibition of neointimal hyperplasia after sirolimus-eluting stent implantation: long-term (up to 2 years) clinical, angiographic, and intravascular ultrasound follow-up. Circulation. 2002;106:1610-1613.
17. Sousa JE, Costa MA, Abizaid AC, et al. Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. Circulation. 2001:104;2007-2011.
18. Heitman J, Movva NR, Hall MN. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science. 1991;253:905-909.
19. Baran DA, Segura L, Kushwaha S, et al. Tacrolimus monotherapy in adult cardiac transplant recipients: intermediate-term results. J Heart Lung Transplant. 2001;20:59-70.
20. Klauss V, Konig A, Spes C, et al. Cyclosporine versus tacrolimus (FK 506) for prevention of cardiac allograft vasculopathy. Am J Cardiol. 2000;85:266-269.
21. Baran DA, Galin I, Sandler D, et al. Tacrolimus in cardiac transplantation: efficacy and safety of a novel dosing protocol. Transplantation. 2002;74:1136-1141.
22. Cooper M, Gregory S, Starzl T, et al. Rapamycin but not FK506 inhibits the proliferation of mononuclear phagocytes induced by colony-stimulating factors. Transplantation. 1994;57:433-439.
23. Izutani H, Miyagawa S, Shirakura R, et al. Recipient macrophage depletion reduces the severity of graft coronary arteriosclerosis in the rat retransplantation model. Transplant Proc. 1997;29:861-862.
24. Russell PS, Chase CM, Sykes M, et al. Tolerance, mixed chimerism, and chronic transplant arteriopathy. J Immunol. 2001;167:5731-5740.
25. Bramhall J, Hobbes T. The questions concerning liberty, necessity and chance. 1659, In: Molesworth W, ed. The English Works of Thomas Hobbes. London: John Bohn; 1841:117.
26. Brara PS, Moussavian M, Grise MA, et al. Pilot trial of oral rapamycin for recalcitrant restenosis. Circulation. 2003;107:1722-1724.